News for INmune Bio, Inc. (INMB)

BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the ”œCompany”), a clinical-stage biotechnology company targeting inflammation

BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targe...

INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsDavid Moss - Chief Financial OfficerDr.

**media[619704]**

Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the â\u0080\u009cCompanyâ\u0080\u009d), a clinical-stage inflammation and immunology company targ

Shares of Calix, Inc. CALX rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued st...

INmune Bio, Inc. (INMB) has achieved a significant milestone in the development of its innovative CORDStrom product, a next-generation mesenchymal stromal cell

\n INmune Bio Inc. (INMB) obtains a favorable USPTO patent opinion for its CORDStromâ\u0084¢ platform. Potential IP protection extends until 2045, boosting mark

Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB), a clinical-stage biotechnology company targeting inflammation and immuno

**media[596621]**

Net Loss: Approximately $42.1 million for the year ended December 31, 2024, compared to approximately $30 million for 2023.Research and Development Expenses: A

Mar 27, 2025 / 08:30PM GMTOperator Greetings and welcome to the Immune BIO's 2024 4th quarter and full year earnings call. (Operator Instructions) As a reminder

Discover key insights from INmune Bio's Q4 2024 earnings: Alzheimer's trial data due in June, oncology advancements, and groundbreaking RDEB treatments.

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsDavid Moss - CFORaymond Tesi - CEO &...

Company to Host Conference Call Today, March 27, at 4:30pm ET BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the ”œCompany”

Revenue: Reported revenue of $0.01 million, meeting the estimated revenue target.Earnings Per Share (EPS): Reported EPS of -$0.53, meeting the estimated EPS.Ph

Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the ”œCompany”), a clinical-stage inflammation and immunology company, to

Transaction Overview On March 12, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 1,999,380 shares of OKYO Pharma L

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click here to read why INMB is a Strong Buy.